Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials-Reference-Cited by-同舟云学术

Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials

Published:2018-05-18 Issue:10 Volume:24 Page:2278-2284
ISSN:1078-0998
Container-title:Inflammatory Bowel Diseases
language:en
Short-container-title:

Author:

Singh Siddharth¹²,Proudfoot James³,Xu Ronghui⁴,Sandborn William J¹

Affiliation:

1. Division of Gastroenterology, University of California San Diego, La Jolla, California, USA

2. Division of Biomedical Informatics, University of California San Diego, La Jolla, California, USA

3. Biostatistics Unit, Altman Clinical and Translational Research Institute, University of California San Diego, La Jolla, California, USA

4. Department of Family Medicine and Public Health and Department of Mathematics, University of California San Diego, La Jolla, California, USA

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Gastroenterology,Immunology and Allergy

Link

http://academic.oup.com/ibdjournal/article-pdf/24/10/2278/25739023/izy135.pdf

Reference16 articles.

1. Obesity in inflammatory bowel disease: a marker of less severe disease;Flores;Dig Dis Sci,2015

2. Body mass index, genetic susceptibility, and risk of complications among individuals with Crohn’s disease;Pringle;Inflamm Bowel Dis,2015

3. Impact of obesity on the management and clinical course of patients with inflammatory bowel disease;Seminerio;Inflamm Bowel Dis,2015

4. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes;Singh;Nat Rev Gastroenterol Hepatol,2017

5. Measures of obesity and risk of Crohn’s disease and ulcerative colitis;Khalili;Inflamm Bowel Dis,2015

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher Intra-Abdominal Visceral Adipose Tissue Mass Is Associated With Lower Rates of Clinical and Endoscopic Remission in Patients With Inflammatory Bowel Diseases Initiating Biologic Therapy: Results of the Constellation Study;Gastroenterology;2023-10

2. Integrating the serum proteomic and fecal metaproteomic to analyze the impacts of overweight/obesity on IBD: a pilot investigation;Clinical Proteomics;2023-02-09

3. Prevalence and associated factors of obesity in inflammatory bowel disease: A case-control study;World Journal of Gastroenterology;2020-12-21

4. Obesity and infl ammatory bowel disease: is there a link?;Experimental and Clinical Gastroenterology;2020-10-30

5. BMI in the lower and upper quartiles at diagnosis and at 1-year follow-up is significantly associated with higher risk of disease exacerbation in pediatric inflammatory bowel disease;European Journal of Pediatrics;2020-06-04